眾業達(002441.SZ):中植不再是公司持股5%以上股東
格隆匯7月21日丨眾業達(002441.SZ)公佈,截至2021年7月21日,中植減持公司股票計劃期限已屆滿。2021年7月21日,公司收到中植出具的《關於股份減持計劃期限屆滿暨減持後持股比例低於5%的吿知函》及《簡式權益變動報吿書》,中植不再是公司持股5%以上股東。
自減持預披露公吿發布之日起十五個交易日後即2021年6月22日至2021年7月21日,中植通過金鷹基金-浦發銀行-金鷹中植產投定增1號資產管理計劃以集中競價交易方式減持公司股份35.07萬股。
此次權益變動後,股東中植產業投資有限公司(“中植”)持有的公司股份比例下降至4.99999%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.